Cadrenal Therapeutics, Inc. (CVKD)
Company Description
Cadrenal Therapeutics is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Most approved drugs, including warfarin, the only FDA-approved Vitamin K antagonists, or VKAs, which is a prescribed drug for the treatment of thrombosis, are metabolized in the liver through a pathway known as the Cytochrome CYP450 system, or CYP450, by the enzymes known as CYP2C9 and CYP3A4.
Patients taking multiple medications that interact with CYP2C9, or CYP3A4 or those with impaired kidney function, can experience an overload in the pathway, creating a bottleneck that often leads to insufficient clearance, which results in a toxic build-up of one or more drugs.
Our product candidate tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
We believe this may allow elimination by large capacity and non-saturable tissue esterase pathways that exist throughout the body rather than just in the liver.
We secured the rights to tecarfarin on April 1, 2022. In 2019, the United States Food and Drug Administration provided input on the Phase 3 trial design for tecarfarin, which was submitted by Espero, the previous owner of tecarfarin.
We intend to submit our Phase 3 trial design to the FDA using the same protocol that was submitted by Espero.
Assuming the FDA accepts our Phase 3 trial design, we intend to commence the Phase 3 pivotal trial in the second half of 2023.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Quang Pham |
Contact Details
Address:
822 A1A North, Suite 320 Ponte Vedra, FL 32082 United States | |
| Phone | (904) 300-0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001937993 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang Pham | Chairman and Chief Executive Officer |
| Matthew Szot | Acting Chief Financial Officer (Chief Financial Officer upon completion of this offering) |
| Douglas Losordo | Acting Chief Medical Officer (Chief Medical Officer upon completion of this offering) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 25, 2023 | 8-K | Current Report |
| Jan 24, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 23, 2023 | 424B4 | Prospectus |
| Jan 23, 2023 | 424B4 | Prospectus |
| Jan 20, 2023 | CERT | Certification by an exchange approving securities for listing |
| Jan 19, 2023 | EFFECT | Notice of Effectiveness |
| Jan 17, 2023 | 8-A12B | Registration of securities |
| Jan 17, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 28, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 8, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |